Orchid Pharma Q2 FY26: revenue down YoY, standalone profit plunges

Qualified OpinionRevenue DeclineEbitda Margin CompressionPat NegativeResults View source PDF Explain this filing

ORCHPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.1%Reaction day

₹853.00

prior close

₹826.20

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%-3.8% vs market

Pharmaceuticals peers, median of 157sector-0.2%-3.9% vs sector

On the reaction day the stock moved 3.8 pts less than Nifty Microcap 250 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.1-0.3-3.8-0.2-3.9

Next day

-7.0+0.7-7.7+0.5-7.5

-6.9+0.6-7.5+0.6-7.5

-6.0+0.5-6.5+0.5-6.5

+1.1+1.1-0.0+0.2+0.9

-1.1+0.3-1.4-0.6-0.6

+2.0-0.2+2.2-1.1+3.1

15d

+0.1-2.2+2.3-2.1+2.2

-0.9-4.9+4.0-3.2+2.2

-15.6-7.5-8.1-5.8-9.7

-19.1-4.8-14.3-6.4-12.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone Q2 FY26 net sales fell to Rs 193.52 crore from Rs 222.70 crore YoY. Standalone PAT dropped to Rs 2.23 crore vs Rs 25.63 crore. Consolidated PAT turned into a Rs 5.72 crore loss vs Rs 27.24 crore profit last year. H1 FY26 revenue fell 21.6% YoY standalone. Company completed Allecra Therapeutics acquisition, repatriating antibiotic Enmetazobactam to India. Amalgamation with Dhanuka Labs pending at NCLT. Auditor issued qualified conclusion on consolidated results.

Likely market impact

Weak quarter with sharp profit decline. Consolidated loss and qualified auditor opinion are negatives. Allecra acquisition may support long-term growth.